Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

CICLUM FARMA UNIPESSOAL, LDA

NIF 504362674
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €2,527,151 44 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €2,527,151 44 contracts
A2 · Late Publication €2,014,739,160 413 contracts
Contract published to BASE more than 10 days after the signing date
LOW €2,014,739,160 413 contracts
A5 · Threshold Splitting €646,118 18 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €646,118 18 contracts
A6 · Low Competition €35,272 3 contracts
Only one bidder participated in a competitive procedure
MEDIUM €35,272 3 contracts
A9 · Abnormal Price Reduction €2,934,577,162 309 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €2,934,577,162 309 contracts
B5 · Benford's Law Deviation €630,460,246 2 contracts
Entity's contract values deviate from the Benford leading-digit distribution (chi-square goodness-of-fit, min 20 contracts). Score: 35 (p<0.05) or 55 (p<0.01).
MEDIUM €630,460,246 2 contracts
C3 · Missing Mandatory Fields €474,098 15 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €474,098 15 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

41
€463,924,778
10
€440,855,345
13
€400,896,586
21
€115,793,542
94
€100,022,358
17
€97,222,905
9
€83,804,319
29
€80,852,086
8
€72,370,219
21
€70,571,471
10
€70,044,737
8
€68,011,959
9
€64,361,050
11
€63,613,534
11
€62,513,819
16
€61,890,612
11
€55,285,083
11
€54,922,525
9
€51,708,613
18
€45,684,435
Page 1 of 3 · 49 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Abnormal Price Reduction B5 · Benford's Law Deviation C3 · Missing Mandatory Fields

Page 1 of 1 · 2 contracts

1329/2025 - Convite à apresentação de propostas ao abrigo do(s) acordo(s)-quadro 2022/0014 (Medicamentos do aparelho digestivo), 2022/0019 (Medicamentos antipsicóticos, anestésicos e relaxantes musculares), 2022/0055 (Medicamentos diversos), 2022/0173 (Medicamentos diversos), 2023/0304 (Medicamentos do grupo 4: sangue), 2023/0305 (Medicamentos do aparelho cardiovascular), 2023/0436 (Medicamentos para o sistema nervoso central), 2023/0437 (Medicação antialérgica, vitaminas e sais minerais e medicamentos usados no tratamento de intoxicações), 2023/0481 (Medicamentos diversos), 2023/0490 (Medicamentos usados em afeções cutâneas), 2023/0491 (Medicamentos do foro oncológico e imunomoduladores), 2023/0492 (Medicamentos anti-infeciosos), 2023/0671 (Medicamentos diversos), 2024/0780 (Medicamentos do aparelho locomotor, usados no tratamento das doenças endócrinas e hormonas), 2024/0782 (Medicamentos usados em afeções oculares e otorrinolaringológicas), 2024/0898 (Medicamentos analgésicos, antip
PT · 11310196 · Ao abrigo de acordo-qu...
A2 · Late Publication A9 · Abnormal Price Reduction +1
€315,230,123 2025-03-14
1329/2025 - Convite à apresentação de propostas ao abrigo do(s) acordo(s)-quadro 2022/0014 (Medicamentos do aparelho digestivo), 2022/0019 (Medicamentos antipsicóticos, anestésicos e relaxantes musculares), 2022/0055 (Medicamentos diversos), 2022/0173 (Medicamentos diversos), 2023/0304 (Medicamentos do grupo 4: sangue), 2023/0305 (Medicamentos do aparelho cardiovascular), 2023/0436 (Medicamentos para o sistema nervoso central), 2023/0437 (Medicação antialérgica, vitaminas e sais minerais e medicamentos usados no tratamento de intoxicações), 2023/0481 (Medicamentos diversos), 2023/0490 (Medicamentos usados em afeções cutâneas), 2023/0491 (Medicamentos do foro oncológico e imunomoduladores), 2023/0492 (Medicamentos anti-infeciosos), 2023/0671 (Medicamentos diversos), 2024/0780 (Medicamentos do aparelho locomotor, usados no tratamento das doenças endócrinas e hormonas), 2024/0782 (Medicamentos usados em afeções oculares e otorrinolaringológicas), 2024/0898 (Medicamentos analgésicos, antip
PT · 11464681 · Ao abrigo de acordo-qu...
A2 · Late Publication A9 · Abnormal Price Reduction +1
€315,230,123 2025-02-28
Overview
Total Value Won
€2,943,900,376
Contracts Won
594
Score 22910 · CRITICAL RISK
NIF
504362674
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • A.M. [P-aece]
    Gerente
    since 2022-07-27
  • B.N. [P-d403]
    Gerente
    since 2019-08-21
  • M.M. [P-4ff7]
    Gerente
    since 2023-12-19
  • E.H. [P-3e64]
    Gerente
    2017-11-29 → 2021-05-31
  • L.M. [P-08a3]
    Gerente
    2013-06-17 → 2017-11-29
  • M.M. [P-33ef]
    Gerente
    until 2013-06-12
  • R.T. [P-a81e]
    Gerente
    2019-08-21 → 2023-12-19
  • T.S. [P-11d3]
    Gerente
    2020-06-24 → 2022-07-27
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned